杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/11/14 | 1,806 | 1,810 | 1,797 | 1,799 | +2 | +0.1% | 54,600 |
2023/11/13 | 1,816 | 1,817 | 1,786 | 1,797 | -23 | -1.3% | 72,800 |
2023/11/10 | 1,786 | 1,821 | 1,770 | 1,820 | +23 | +1.3% | 124,500 |
2023/11/09 | 1,806 | 1,806 | 1,786 | 1,797 | -19 | -1% | 125,000 |
2023/11/08 | 1,827 | 1,829 | 1,796 | 1,816 | -2 | -0.1% | 91,000 |
2023/11/07 | 1,804 | 1,826 | 1,798 | 1,818 | +18 | +1% | 80,200 |
2023/11/06 | 1,820 | 1,821 | 1,800 | 1,800 | -7 | -0.4% | 89,200 |
2023/11/02 | 1,804 | 1,810 | 1,793 | 1,807 | +12 | +0.7% | 81,700 |
2023/11/01 | 1,793 | 1,800 | 1,780 | 1,795 | +17 | +1% | 107,100 |
2023/10/31 | 1,735 | 1,779 | 1,735 | 1,778 | +44 | +2.5% | 116,900 |
2023/10/30 | 1,758 | 1,758 | 1,728 | 1,734 | -40 | -2.3% | 102,200 |
2023/10/27 | 1,754 | 1,774 | 1,743 | 1,774 | +21 | +1.2% | 92,600 |
2023/10/26 | 1,768 | 1,783 | 1,749 | 1,753 | -15 | -0.8% | 108,500 |
2023/10/25 | 1,795 | 1,795 | 1,768 | 1,768 | -14 | -0.8% | 108,200 |
2023/10/24 | 1,781 | 1,785 | 1,758 | 1,782 | -6 | -0.3% | 78,800 |
2023/10/23 | 1,785 | 1,800 | 1,777 | 1,788 | +3 | +0.2% | 58,300 |
2023/10/20 | 1,791 | 1,797 | 1,772 | 1,785 | -8 | -0.4% | 56,900 |
2023/10/19 | 1,778 | 1,803 | 1,778 | 1,793 | +4 | +0.2% | 66,100 |
2023/10/18 | 1,787 | 1,796 | 1,767 | 1,789 | +2 | +0.1% | 90,600 |
2023/10/17 | 1,782 | 1,793 | 1,775 | 1,787 | +5 | +0.3% | 52,000 |
2023/10/16 | 1,808 | 1,810 | 1,781 | 1,782 | -24 | -1.3% | 43,600 |
2023/10/13 | 1,819 | 1,833 | 1,798 | 1,806 | -28 | -1.5% | 71,200 |
2023/10/12 | 1,840 | 1,840 | 1,820 | 1,834 | -6 | -0.3% | 55,600 |
2023/10/11 | 1,833 | 1,847 | 1,822 | 1,840 | +9 | +0.5% | 82,700 |
2023/10/10 | 1,800 | 1,834 | 1,800 | 1,831 | +19 | +1% | 79,400 |
2023/10/06 | 1,793 | 1,829 | 1,793 | 1,812 | +6 | +0.3% | 68,400 |
2023/10/05 | 1,780 | 1,809 | 1,777 | 1,806 | +15 | +0.8% | 85,100 |
2023/10/04 | 1,794 | 1,813 | 1,780 | 1,791 | -21 | -1.2% | 81,600 |
2023/10/03 | 1,821 | 1,836 | 1,812 | 1,812 | -2 | -0.1% | 89,300 |
2023/10/02 | 1,847 | 1,850 | 1,814 | 1,814 | -17 | -0.9% | 105,800 |
2023/09/29 | 1,855 | 1,858 | 1,817 | 1,831 | -22 | -1.2% | 87,000 |
2023/09/28 | 1,831 | 1,863 | 1,819 | 1,853 | -10 | -0.5% | 149,800 |
2023/09/27 | 1,833 | 1,864 | 1,819 | 1,863 | +28 | +1.5% | 122,100 |
2023/09/26 | 1,830 | 1,845 | 1,820 | 1,835 | +11 | +0.6% | 90,400 |
2023/09/25 | 1,800 | 1,830 | 1,791 | 1,824 | +42 | +2.4% | 133,800 |
2023/09/22 | 1,796 | 1,803 | 1,780 | 1,782 | -26 | -1.4% | 78,500 |
2023/09/21 | 1,806 | 1,824 | 1,803 | 1,808 | +1 | +0.1% | 67,300 |
2023/09/20 | 1,834 | 1,834 | 1,805 | 1,807 | -27 | -1.5% | 102,400 |
2023/09/19 | 1,815 | 1,834 | 1,815 | 1,834 | +3 | +0.2% | 58,500 |
2023/09/15 | 1,812 | 1,842 | 1,801 | 1,831 | +24 | +1.3% | 217,700 |
2023/09/14 | 1,800 | 1,810 | 1,790 | 1,807 | +8 | +0.4% | 110,800 |
2023/09/13 | 1,800 | 1,801 | 1,789 | 1,799 | -1 | -0.1% | 68,500 |
2023/09/12 | 1,779 | 1,802 | 1,778 | 1,800 | +22 | +1.2% | 55,200 |
2023/09/11 | 1,773 | 1,780 | 1,764 | 1,778 | +4 | +0.2% | 41,400 |
2023/09/08 | 1,783 | 1,795 | 1,771 | 1,774 | -7 | -0.4% | 102,700 |
2023/09/07 | 1,775 | 1,785 | 1,770 | 1,781 | -1 | -0.1% | 83,600 |
2023/09/06 | 1,798 | 1,798 | 1,776 | 1,782 | -9 | -0.5% | 42,600 |
2023/09/05 | 1,787 | 1,800 | 1,779 | 1,791 | +2 | +0.1% | 84,200 |
2023/09/04 | 1,788 | 1,792 | 1,775 | 1,789 | -5 | -0.3% | 60,600 |
2023/09/01 | 1,773 | 1,797 | 1,766 | 1,794 | +20 | +1.1% | 130,700 |
251~
300
件表示中 / 3585件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 149,100円 | +3.2% | +4.5% | 3.49% | 17.13倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ゼリア新薬 | 222,100円 | +13.6% | +29.2% | 2.07% | 11.52倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,700円 | +197.7% | - | 0.00% | 46.47倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 69,600円 | -3.7% | -36.7% | 2.87% | 22.92倍 | 1.50倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
栄研化 | 210,100円 | +0.4% | -8.4% | 2.52% | 27.77倍 | 1.58倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム